FDA Panel to Discuss Boosters, COVID-19 Vaccine for Children in Upcoming Meetings
Background materials for both meetings will be available to the public.
Diagnosis & Disease Information
mRNA-1273 Continues to Be Efficacious at Five Months
Vaccine efficacy was 98.2% for preventing severe COVID-19.
Vaccines Effective in Preventing Symptomatic COVID-19 in Health Care Workers
Vaccine effectiveness was 88.8% for Pfizer-BioNTech and 96.3% for Moderna.
Antibodies ID’d in Neonates of Women Vaccinated Against COVID-19
All 36 neonates had high levels of anti-S IgG.
Moderna Vaccine Top for Protection Against COVID-19 Hospitalization
Vaccine effectiveness higher for Moderna than Pfizer-BioNTech vaccine; both mRNA vaccines have higher VE than Janssen.
Most Solid Tumor Patients Have ‘Adequate’ Response to COVID-19 Vaccination, Regardless of Treatment
Responses in cancer patients were noninferior to responses in patients without cancer.
BNT162b2 Elicits Lower Antibody Levels Than mRNA-1273 Vaccine
Levels of IgG to SARS-CoV-2 spike receptor binding domain also lower with BNT162b2 for those aged 50 years and older versus younger than 50.
COVID-19 Vaccine Effectiveness Changing With Delta Predominance
Increasing prevalence of the delta variant was linked to a decline in vaccine protection against SARS-CoV-2 infection but not hospitalization or death.
Interim Data Show No Increase in Serious Outcomes Post-COVID-19 Vaccination
The incidence of ischemic stroke, appendicitis, or acute myocardial infarction were not increased 1 to 21 days after mRNA COVID-19 vaccination.
mRNA COVID-19 Vaccines Immunogenic in Immunosuppressed Patients
Titers of anti-S IgG were lower for patients with chronic inflammatory disease receiving glucocorticoids or B-cell depleting therapy.
- Loading...
Loading...
Next post in General Medicine
Loading... 
Loading...